Kejian Zhang1, Changyuan Li2, Mingrui Zhang3, Yang Li4. 1. Department of Thoracic Surgery, Jilin Cancer Hospital, Chang Chun, Jilin, 130021, People's Republic of China. 2. Department of Thoracic Surgery, First Hospital of Jilin University, Xinmin street 71, Chang Chun, 130021, People's Republic of China. 3. Hospital of Stomatology, Jilin University, Chang Chun, 130021, People's Republic of China. 4. Department of Thoracic Surgery, First Hospital of Jilin University, Xinmin street 71, Chang Chun, 130021, People's Republic of China. li_yang1973@yeah.net.
Abstract
BACKGROUND: To retrospectively assess the efficacy of hypertonic glucose pleurodesis for treatment of chylothorax after pulmonary resection. METHODS: Out of a total of 8252 patients who underwent pulmonary resection (at least lobectomy) at department of thoracic surgery, between June 2008 and December 2015, 58 patients (0.7%) developed postoperative chylothorax. All patients received conservative treatment, including thoracic closed drainage, oral fasting, and total parenteral nutrition. RESULTS: Conservative treatment was successful in 50 (86.2%) patients, while eight patients [mean age: 58.0 years (range, 45-75)] were treated with hypertonic glucose pleurodesis. All eight patients had undergone operation for lung cancer (four squamous cell carcinomas and four adenocarcinomas). The bronchial stump was covered by pleural flap in three patients. After pleurodesis, three patients developed fever but without empyema; thoracentesis was performed in two patients. The mean time interval between pleurodesis and operation was 4.3 days (range,3-5) days. The average length of stay was 23.1 days (range, 18-31). No recurrent pleural effusion was observed over a mean follow-up duration of 28 months. CONCLUSION: Hypertonic glucose pleurodesis performed via the chest drainage tube is a viable treatment option for chylothorax after lung resection, prior to resorting to a thoracoscopic or thoracotomic ductus thoracicus ligation of the thoracic duct leak. It is a simple, safe and efficient modality associated with rapid recovery and less pain.
BACKGROUND: To retrospectively assess the efficacy of hypertonic glucose pleurodesis for treatment of chylothorax after pulmonary resection. METHODS: Out of a total of 8252 patients who underwent pulmonary resection (at least lobectomy) at department of thoracic surgery, between June 2008 and December 2015, 58 patients (0.7%) developed postoperative chylothorax. All patients received conservative treatment, including thoracic closed drainage, oral fasting, and total parenteral nutrition. RESULTS: Conservative treatment was successful in 50 (86.2%) patients, while eight patients [mean age: 58.0 years (range, 45-75)] were treated with hypertonic glucose pleurodesis. All eight patients had undergone operation for lung cancer (four squamous cell carcinomas and four adenocarcinomas). The bronchial stump was covered by pleural flap in three patients. After pleurodesis, three patients developed fever but without empyema; thoracentesis was performed in two patients. The mean time interval between pleurodesis and operation was 4.3 days (range,3-5) days. The average length of stay was 23.1 days (range, 18-31). No recurrent pleural effusion was observed over a mean follow-up duration of 28 months. CONCLUSION:Hypertonic glucose pleurodesis performed via the chest drainage tube is a viable treatment option for chylothorax after lung resection, prior to resorting to a thoracoscopic or thoracotomic ductus thoracicus ligation of the thoracic duct leak. It is a simple, safe and efficient modality associated with rapid recovery and less pain.
Authors: Kari J Thompson; Kemp H Kernstine; Frederic W Grannis; Pablo Mojica; Andres Falabella Journal: Ann Thorac Surg Date: 2008-01 Impact factor: 4.330
Authors: A Gómez-Caro Andrés; C Marrón Fernández; F J Moradiellos Díez; V Díaz-Hellín Gude; J A Pérez Antón; J L Martín de Nicolás Journal: Arch Bronconeumol Date: 2004-10 Impact factor: 4.872
Authors: Charles C Roehr; Andreas Jung; Hans Proquitté; Oliver Blankenstein; Hannes Hammer; Kokila Lakhoo; Roland R Wauer Journal: Intensive Care Med Date: 2006-03-11 Impact factor: 17.440